LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)

Jonathan E. Rosenberg, M. Milowsky, Chethan Ramamurthy, Nataliya Mar, Rana R. McKay, Terence W. Friedlander, C. Ferrario, Sergio Bracarda, Saby George, Helen Moon, Daniel M. Geynisman, Daniel P. Petrylak, Delphine Borchiellini, Earle F. Burgess, J.P. Maroto Rey, A-S. Carret, Yao Yu, Maria Guseva, Blanca Homet Moreno, Peter H. O’Donnell